• CAS Science Spotlight Home
• Most Cited Journal Articles 2005-Medical Sciences
• About
• What's New

Home   •   Spotlight  •  medsci05  •  Most Cited Journal Articles 2005-Medical Sciences (5)

Most Cited Journal Articles 2005-Medical Sciences

Following is a CAS database record representing a highly cited journal article.

---

CAS indexed 5 chemical substances from this document. CAS subject entries for this document include: Lung, neoplasm; DNA sequences; Antitumor agents; and 5 additional concepts.

CAPLUS COPYRIGHT 2006 ACS on STN

TITLE:	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
AUTHOR(S):	Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew
CORPORATE SOURCE:	Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
SOURCE:	Science (Washington, DC, United States) (2004), 304(5676), 1497-1500 CODEN: SCIEAS; ISSN: 0036-8075
PUBLISHER:	American Association for the Advancement of Science
LANGUAGE:	English

ABSTRACT:
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.